Administrative structure

Board of Directors
David J. Sugarbaker, MD, Program Director
Raphael Bueno, MD, Research Co-Director
Lambros Zellos, MD, Clinical Co-Director
Maggie Derival, Administrative Coordinator

Executive Advisory Board
Limited to 5 members, the Executive Board provides the lay perspective, representing organizations focused on and impacted by this disease. The Board receives quarterly research updates and meets semi-annually, allowing for feedback and presentation of research progress and providing a medium for the exchange of ideas. Board members may be asked to provide specific input on an as needed basis and to serve as a liaison as the research interfaces with the various lay disciplines associated with this disease.

Executive Advisory Board Members
Baron and Budd, P.C., Attorneys at Law
3102 Oak Lawn Avenue, Ste 1100
Dallas, Texas 75219

The Ferraro Law Firm
4000 Ponce de Leon Blvd
Miami, FL 33146

Motley Rice, LLC, Attorneys at Law
PO Box 1792
Mt Pleasant, SC 29465

Thornton & Naumes, LLP, Attorneys at Law
100 Summer Street, 30th FL
Boston, MA 02110

SimmonsCooper, LLC, Attorneys at Law
707 Berkshire Blvd.
PO Box 521
East Alton, IL 62024

Scientific Advisory Board
A Scientific Advisory Board (SAB) was created to provide an expert and objective review of the science, make sure it stands up to peer review and remain cutting edge and state-of-the-art. The Board includes internationally recognized experts in mesothelioma, representing a variety of fields including epidemiology, biology, pathology, pharmacology, oncology, and surgery.

The Board also includes three Patient Advocates who provide both the patient and caregiver perspectives. We are measuring with validated instruments the impact of this disease on patient and caregiver quality of life, and our advocates give us first hand guidance on where to concentrate our research in this area.

The SAB will meet at least once a year at the Annual Retreat to give objective advice and evaluation, and make recommendations for future research plans. The Board’s recommendations will be summarized in a written report and implemented by Dr. Sugarbaker.

Scientific Advisory Board Members

Paul J. Catalano, ScD	Dana-Farber Cancer Institute	Statistician
Bruce A. Chabner, MD	Massachusetts General Hospital	Oncologist
Jerry M. Collins, PhD	US Food and Drug Administration	Pharmacologist
Graham A.Colditz, MD	BWH Channing Laboratory	Epidemiologist
Adi Gazdar, MD	UT Southwester Medical Center at Dallas	Basic Scientist
Samuel Hammer, MD	Diagnostic Specialty Labs	Pathologist
Hedy Lee Kindler, MD	University of Chicago	Oncologist
Eric S. Lander, Ph.D.	Broad Institute of MIT and Harvard	Basic Scientist
John Lechner, PhD	Bayer Corporation	Basic Scientist
David G. Nathan, MD	President Emeritus, DFCI	Oncologist
John Peters, MD, ScD	Keck, USC School of Medicine	Epidemiologist
Thomas M. Roberts, PhD	Dana-Farber Cancer Institute	Basic Scientist
Jack A. Roth, MD	UT Southwestern MD Anderson	Surgeon
Steven D. Shapiro, MD	Brigham and Women’s Hospital	Pulmonologist
Gary Strauss, MD	Brown Medical School	Oncologist
Linda Garmon	Cambridge, MA	Patient Advocate
Elaine Hoffman	Savannah, GA	Patient Advocate
Karen Grant	Methuen, MA	Patient Advocate

The Board of Visitors, limited to 30 members, are key partners who will lend international support and exposure to the Program by publicly generating greater awareness of the disease in their sphere of influence.

Members of the Board of Visitors will be invited to an annual research update meeting in Boston and will be thanked for their gift on our website and in our Annual Report. They will be joining a dedicated team pursuing one goal: helping mesothelioma patients by pursuing  quality of life extension, leading to a cure.